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abstract iNtroductioN
Stent thrombosis is a catastrophic complication of percutaneous coronary intervention (PCI) and is associated with a mortality of between 25 to 40%. Various trials report the frequency of stent thrombosis as (0.8-2%). (1, 2) Most evaluations however come from registries that are likely to underestimate the real prevalence.
The perception that stent thrombosis is very low in all patients has resulted in a lack of adherence to professional guidelines. (4) New data to identify patients at increased risk for stent thrombosis are emerging. The COURAGE and FAME trials should have tempered over-exuberant PCI, and hopefully now the interventionalists will also be proactive in seeking out the patient at higher risk for stent thrombosis. Numerous risk factors for stent thrombosis have been established (Table 1) . (5, 6) stent thrombosis is a catastrophic complication of percutaneous coronary intervention (Pci) and is associated with a mortality of 25 to 40%. the perception that stent thrombosis is very low in all patients has resulted in a lack of adherence to professional guidelines. New data to identify patients at increased risk for stent thrombosis are emerging.
clopidogrel is a prodrug and the activation of clopidogrel is dependent on cY2c19. Clopidogrel is a prodrug. After absorption 85% is converted into an inactive form by esterases. Only 15% is then available for conversion to its active metabolite. This conversion process is complex and involves numerous enzymes. CYP2C19 in particular is required at two separate oxidative steps ( Figure 2 ).
Eighty-five percent of absorbed clopidogrel is converted into an inactive form by esterases. Only 15% is then available for conversion to its active metabolite. Clopidogrel activation is dependent on CYP2C19 as it is involved in both of the hepatic oxidative steps.
Basic pharmacogenetics of clopidogrel
Numerous alleles of CYP2C19 exist. The allele CYP2CP*2 has been associated with a loss of function which results in a marked decrease in platelet responsiveness to clopidogrel. (8) The presence of genetically poorly functioning CYP2C19*2 has been shown to effect clopidogrel activation, especially when it is present in the homozygous state (CYP2C19*2/*2).
The FAST-MI study demonstrated an association between stent thrombosis and CYP2C19*/*. The TRITON TIMI 38 study demonstrated an association between stent thrombosis CYP2C19* and CYP2C19*/*. (10, 11) A recent collaborative meta-analysis involving 9 studies presented at the American Heart Association in November 2009 by Mega, revealed that heterozygote carriers of the CYP2C19*2, had a 2.7-fold increased risk and homozygotes a 4.8-fold increased risk of stent thrombosis. In this meta-analysis, 26% of the population were heterozygous carriers of the variant allele and 2% were homozygous carriers. 
Drug interactions
PPIs are metabolised by CYP2C19 and may therefore compete for CYP2C19 when used in conjunction with clopidogrel.
There have been numerous observational studies which suggest that the clopidogrel and PPI interaction can lead to adverse cardiovascular outcomes (14) (Figure 3) . Omeprazole, in particular, has been incriminated while pantoprazole has reputedly less interaction with PPIs. (15) In the subgroup analyses of the CREDO and TRITON trials (16, 17) was associated with less stent thrombosis. There was no increased risk of bleeding when the TIMI major bleeding criteria were used.
There was however a small increased risk of red cell transfusion.
Point-of-care platelet-function tests are becoming available and some centres are now performing such tests on their PCI patients.
Unfortunately, there is no evidence that modifying the treatment of a hypo-responsive patient improves outcomes. Numerous trials are being conducted in this regard:
GRAVITAS (Gauging Responsiveness with a Verify Now AssayImpact on Thrombosis and Safety) trial, randomising patients deemed non-responsive to clopidogrel on point-of-care testing to receive higher dosing of clopidogrel. 
